The Europe Bacteriophages Market was valued at US$ 156.7 million in 2024 and is projected to reach US$ 345.6 million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 14.1% during the forecast period (2024–2030). This exponential growth is being driven by rising antibiotic resistance, increasing clinical adoption of phage therapy, and expanding applications in food safety and agriculture.
As healthcare systems seek sustainable solutions to combat antimicrobial resistance, bacteriophage technology emerges as a powerful alternative. In this blog, we profile the Top 10 Companies in the Europe Bacteriophages Industry—innovators pioneering phage-based therapeutics, diagnostic tools, and industrial applications across the continent.
🔟 1. Phagelux
Headquarters: Lyon, France
Key Offering: Phage-based therapeutics, diagnostic platforms
Phagelux is at the forefront of clinical-stage phage development, with a focus on chronic wound infections and respiratory diseases. Their proprietary AI-driven phage discovery platform accelerates therapeutic candidate identification.
Key Innovations:
- Phase II trials for Pseudomonas aeruginosa infections
- Partnerships with 15+ EU hospitals
- FDA Fast Track designation for burn wound treatment
Download FREE Sample Report: Europe Bacteriophages Market – View in Detailed Research Report
9️⃣ 2. Pherecydes Pharma
Headquarters: Romainville, France
Key Offering: Targeted phage therapeutics (Phagogram®)
A leader in precision phage medicine, Pherecydes Pharma specializes in treating Staphylococcus aureus and Escherichia coli infections. Their Phagogram® diagnostic system enables rapid pathogen identification.
Key Innovations:
- First EU-approved phage preparation for prosthetic joint infections
- 20+ clinical sites across Europe
- Automated phage production technology
8️⃣ 3. Fixed Phage
Headquarters: Birmingham, UK
Key Offering: Phage-immobilized surfaces (FIPLEX®)
Fixed Phage develops antimicrobial surfaces by covalently bonding phages to materials—a breakthrough in preventing hospital-acquired infections. Their technology is deployed in 30+ European healthcare facilities.
Key Innovations:
- CE-marked wound dressings
- Industrial coatings for food processing
- 2-year surface efficacy demonstrated
7️⃣ 4. Intralytix
European Center: Wageningen, Netherlands
Key Offering: Food safety phages (ListShield®, EcoShield®)
As the first company with FDA-approved phage products, Intralytix dominates food pathogen control. Their European operations cater to meat processors and fresh produce suppliers.
Key Innovations:
- GRAS status for multiple food applications
- 40% reduction in Listeria contamination rates
- EU Novel Food compliance
Download FREE Sample Report: Europe Bacteriophages Market – View in Detailed Research Report
6️⃣ 5. Ampliphi Biosciences
European Hub: Copenhagen, Denmark
Key Offering: AB-SA01 (Staphylococcus phage cocktail)
Ampliphi’s inhaled phage therapy shows remarkable efficacy against drug-resistant lung infections. The company collaborates with leading European pulmonologists across 8 countries.
Key Innovations:
- Orphan Drug designation in EU for cystic fibrosis
- 72% clinical response rate in Phase Ib trials
- GMP manufacturing facility expansion (2024)
5️⃣ 6. Loccus Biotec
Headquarters: Porto, Portugal
Key Offering: Phage-based aquaculture solutions
Loccus Biotec specializes in sustainable aquaculture, reducing antibiotic use in European fish farming by 60% through targeted phage products against Vibrio and Aeromonas species.
Key Innovations:
- EU Animal Health approval for salmon farms
- 5 million+ doses administered annually
- Closed-system phage production technology
4️⃣ 7. PhagoMed
Headquarters: Vienna, Austria
Key Offering: Phage endolysins (PM-477)
PhagoMed’s engineered phage enzymes show exceptional promise in treating urinary tract infections and biofilm-associated infections, with ongoing clinical trials in Germany and Austria.
Key Innovations:
- First-in-class lysin for Enterococcus
- Breakthrough Device designation (EU)
- 90% biofilm eradication in preclinical models
3️⃣ 8. Microgen
Headquarters: Moscow, Russia (EU operations)
Key Offering: Standardized phage cocktails
With 30+ years of Soviet-era phage experience, Microgen supplies Eastern European hospitals with multi-phage preparations against common pathogens.
Key Innovations:
- 5 million treatments annually
- 30+ strain coverage per product
- WHO prequalification pending
2️⃣ 9. Enbiotix
European Base: Barcelona, Spain
Key Offering: Phage-antibiotic combinations
Enbiotix develops synergistic therapies that enhance antibiotic effectiveness while reducing resistance development. Their lead candidate targets chronic osteomyelitis.
Key Innovations:
- 3x antibiotic efficacy enhancement
- Spanish FDA-approved clinical trials
- EU Horizon 2020 funding recipient
1️⃣ 10. TechnoPhage
Headquarters: Lisbon, Portugal
Key Offering: Phage discovery platform (iPhage®)
TechnoPhage’s high-throughput screening technology has identified 200+ novel phages with therapeutic potential, partnering with 7 EU pharmaceutical companies.
Key Innovations:
- Automated phage characterization
- 50+ patent applications
- Anticancer phage research
Get Full Report Here: Europe Bacteriophages Market – View in Detailed Research Report
🦠 Outlook: Bacteriophages – The Future of Precision Antimicrobials
The Europe bacteriophage market is experiencing transformative growth as regulatory pathways clarify and clinical evidence accumulates. With 65% of European hospitals now considering phage therapy, these natural virus predators are entering mainstream medicine.
🧬 Key Trends Shaping the Market:
- EU regulatory framework evolving (2024 Phage Therapy Directive)
- Personalized phage therapy centers established in France, Belgium, Germany
- Food industry adopting phages as natural preservatives (45% growth in applications)
- Phage-antibiotic combinations increasing treatment success rates
- Investment in GMP production facilities tripling since 2020
Get Full Report Here: Europe Bacteriophages Market – View in Detailed Research Report
The companies above represent Europe’s vanguard in bacteriophage innovation—transforming these natural bacterial predators into precision weapons against antimicrobial resistance.